2-(3-甲基咪唑-4-基)乙胺 | 644-42-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 2-(3-甲基咪唑-4-基)乙胺
• 英文名称: 3-methylhistamine
• 英文别名: N^π-methylhistamine；1-methyl-1H-5-histamine；2-(3-methyl-3H-imidazol-4-yl)-ethylamine；2-(3-Methyl-3H-imidazol-4-yl)-aethylamin；2-(1-methyl-1H-imidazol-5-yl)ethanamine；2-(3-methylimidazol-4-yl)ethanamine
• CAS: 644-42-8
• 化学式: C₆H₁₁N₃
• mdl: MFCD08448886
• 分子量: 125.173
• InChiKey: CPAGZVLINCPJEH-UHFFFAOYSA-N

物化性质

• 物理描述：
  Solid
• 碰撞截面：
  123.8 Ų [M+H]+ [CCS Type: DT, Method: single field calibrated with Agilent tune mix (Agilent)]

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933290090

反应信息

• 作为反应物：
  描述：

  2-(3-甲基咪唑-4-基)乙胺 在 2,4,5,6-四甲基苯二磺酸氯 作用下， 以 二氯甲烷 为溶剂， 反应 0.17h， 生成 Dithiophosphoric acid O-[(2R,3S,5R)-2-(bis-(4-methoxy-phenyl)-{3-[2-(3-methyl-3H-imidazol-4-yl)-ethylcarbamoyl]-phenyl}-methoxymethyl)-5-(5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-tetrahydro-furan-3-yl] ester S,S'-diphenyl ester
  参考文献：
  名称：

  新的5'-羟基保护基团可快速形成核苷酸间键

  摘要：

  已经研究了具有用于核苷酸间键形成的催化位点的多种5'-羟基保护基。其中，具有咪唑基乙基氨基甲酰基取代基的改性二甲氧基三苯甲基已被证明是高效的并且优于先前已知的IDTr。

  DOI：

  10.1016/s0040-4039(00)61413-2
• 作为产物：
  描述：

  4(5)-腈甲基咪唑 在 sodium hydroxide 、 乙醇 、 sodium 作用下， 生成 2-(3-甲基咪唑-4-基)乙胺
  参考文献：
  名称：

  Pyman, Journal of the Chemical Society, 1911, vol. 99, p. 2181

  摘要：

  DOI：

文献信息

• Methods for treating an inflammatory condition or inhibiting JNK
  申请人：——

  公开号：US20040127536A1

  公开（公告）日：2004-07-01

  This invention is generally directed to Indazole Derivatives having the following structure: 1 or pharmaceutically acceptable salt thereof, wherein R 1 , R 2 and A are as defined herein. Such compounds have utility in the treatment of a wide range of diseases and disorders that are responsive to JNK inhibition, such as an inflammatory disease or disorder. Thus, methods of treating such diseases and disorders are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.

  这项发明通常涉及吲唑衍生物，具有以下结构： 1 或药用可接受的盐，其中R 1 ，R 2 和A如本文所述定义。这类化合物在治疗对JNK抑制剂有响应的广泛疾病和障碍，如炎症性疾病或障碍中具有用途。因此，还披露了治疗这些疾病和障碍的方法，以及包含一个或多个上述化合物的药物组合物。
• Indazole compounds, compositions thereof and methods of treatment therewith
  申请人：Bhagwat S. Shripad

  公开号：US20050009876A1

  公开（公告）日：2005-01-13

  This invention is generally directed to the use of Indazole Compounds for treating or preventing diseases associated with protein kinases, including tyrosine kinases, such as proliferative diseases, inflammatory diseases, abnormal angiogenesis and diseases related thereto, atherosclerosis, macular degeneration, diabetes, obesity, pain and others. The methods comprise the administration to a patient in need thereof of an effective amount of an indazole compound that inhibits, modulates or regulates tyrosine kinase signal transduction. Novel indazole compounds or pharmaceutically acceptable salt thereof are presented herein.

  这项发明通常涉及使用吲唑化合物来治疗或预防与蛋白激酶相关的疾病，包括酪氨酸激酶，诸如增殖性疾病、炎症性疾病、异常血管生成及其相关疾病、动脉硬化、黄斑变性、糖尿病、肥胖、疼痛等。这些方法包括向有需要的患者施用有效量的吲唑化合物，以抑制、调节或控制酪氨酸激酶信号转导。本文中提供了一种新型的吲唑化合物或其药用可接受的盐。
• [EN] QUINOXALINE COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS À BASE DE QUINOXALINE ET LEURS UTILISATIONS
  申请人：MILLENNIUM PHARM INC

  公开号：WO2015161142A1

  公开（公告）日：2015-10-22

  This invention provides compounds of formula I and subsets thereof: wherein T, J, R, R4, Rq, o, RA, and RB and subsets thereof are as described in the specification. The compounds are inhibitors of NAMPT and are thus useful for treating cancer, inflammatory conditions, or T-cell mediated autoimmune disease.

  这项发明提供了公式I及其子集的化合物：其中T、J、R、R4、Rq、o、RA和RB以及其子集如规范中所述。这些化合物是NAMPT的抑制剂，因此可用于治疗癌症、炎症性疾病或T细胞介导的自身免疫疾病。
• [EN] SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS<br/>[FR] COMPOSÉS PYRAZOLO[1,5-A]PYRIMIDINES SUBSTITUÉES EN TANT QU'INHIBITEURS DES TRK KINASES
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2011006074A1

  公开（公告）日：2011-01-13

  Compounds of Formula (I) and salts thereof in which R1, R2, R3, R4, X, Y and n have the meanings given in the specification, are inhibitors of Trk kinases and are useful in the treatment of diseases which can be treated with a Trk kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.

  式（I）的化合物及其盐，其中R1、R2、R3、R4、X、Y和n的含义如规范中所述，是Trk激酶的抑制剂，并且在治疗可以用Trk激酶抑制剂治疗的疾病中具有用处，如疼痛、癌症、炎症、神经退行性疾病和某些传染病。
• Indazole derivatives as JNK inhibitors and compositions and methods related thereto
  申请人：——

  公开号：US20020103229A1

  公开（公告）日：2002-08-01

  Compounds having activity as selective inhibitors of JNK are disclosed. The compounds of this invention are indazole derivatives having the following structure: 1 wherein R 1 , R 2 and A are as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive to JNK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.

  本发明公开了作为JNK选择性抑制剂的化合物。本发明的化合物是吲唑衍生物，具有以下结构： 1 其中R 1 ，R 2 和A如本文所述定义。此类化合物在治疗对JNK抑制产生响应的广泛病症方面具有用途。因此，还公开了治疗此类病症的方法，以及包含一个或多个上述化合物的药物组合物。